First Financial Bankshares Inc lowered its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 48.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,119 shares of the medical research company’s stock after selling 109,533 shares during the period. First Financial Bankshares Inc’s holdings in Amgen were worth $48,524,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. Quest 10 Wealth Builders Inc. lifted its holdings in shares of Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after purchasing an additional 55 shares during the period. Wellington Altus USA Inc. grew its position in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after buying an additional 34 shares during the last quarter. Nvwm LLC increased its stake in Amgen by 412.5% in the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after buying an additional 66 shares during the period. PFS Partners LLC increased its stake in Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after buying an additional 42 shares during the period. Finally, TOWER TRUST & INVESTMENT Co acquired a new position in Amgen in the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Trading Down 0.7%
Shares of AMGN stock opened at $462.32 on Tuesday. The business’s fifty day moving average price is $425.81 and its 200 day moving average price is $381.77. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The firm has a market capitalization of $250.07 billion, a PE ratio of 20.15, a P/E/G ratio of 3.25 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20.
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $5.64 earnings per share. As a group, sell-side analysts forecast that Amgen Inc. will post 23.37 EPS for the current fiscal year.
Amgen Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is currently 58.47%.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. Cantor Fitzgerald upped their price objective on shares of Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Wells Fargo & Company boosted their price target on shares of Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. TD Cowen boosted their price target on shares of Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Finally, Bank of America increased their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $425.69.
Get Our Latest Report on Amgen
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Stories
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
